Actinium (225ac) Lintuzumab Satetraxetan

Actinium (225ac) Lintuzumab Satetraxetan Uses, Dosage, Side Effects, Food Interaction and all others data.

Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).

Trade Name	Actinium (225ac) Lintuzumab Satetraxetan
Generic	Lintuzumab satetraxetan AC-225
Lintuzumab satetraxetan AC-225 Other Names	225Ac-HuM195, 225Ac-lintuzumab, Actinium (225ac) lintuzumab satetraxetan, Actinium AC 225 lintuzumab, Actinium AC-225 lintuzumab, Actinium-225-labeled humanized anti-cd33 monoclonal antibody HUM195, HUM-195 AC-225, Lintuzumab actinium Ac-225, Lintuzumab satetraxetan AC-225
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here Actinium (225ac) Lintuzumab Satetraxetan